{
    "clinical_study": {
        "@rank": "68836", 
        "arm_group": [
            {
                "arm_group_label": "ACWY-TT group", 
                "arm_group_type": "Experimental", 
                "description": "All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study."
            }, 
            {
                "arm_group_label": "MenPS group", 
                "arm_group_type": "Active Comparator", 
                "description": "All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9\n      to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY\n      when given to healthy subjects 11 to 55 years of age. In addition, the safety and\n      immunogenicity of a booster dose of MenACWY-TT vaccine administered to all eligible subjects\n      10 years after the primary vaccination will be evaluated.\n\n      All Filipino subjects who received the primary vaccination in the primary vaccination study\n      107386 (NCT00356369) will be invited to enrol in the long-term follow up and booster phase.\n      No new subjects will be enrolled."
        }, 
        "brief_title": "Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Meningococcal", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All subjects must satisfy the following criteria at study entry to the persistence phase:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol. Or /and subjects' parent(s)/Legally Acceptable\n             Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will\n             comply with the requirements of the protocol.\n\n          -  A male or female between and including 17 and 66 years of age at the time of entry\n             into the present study.\n\n          -  Has completed the vaccination phase of the vaccination study MENACWY-TT-015.\n\n          -  In alignment with local laws and regulations, written informed consent obtained from\n             parents/LAR(s) of the subject and written informed assent obtained from the subject\n             if the subject is less than 18 years of age, or written informed consent obtained\n             from the subject if the subject has achieved the 18th birthday. The subjects \u226518\n             years of age at the time of enrollment will sign the informed consent form, even if\n             the parent/ LAR previously signed the ICF before the subject reached the legal age of\n             consent.\n\n          -  Healthy subjects as established by medical history and history-directed physical\n             examination before entering into the study.\n\n        All subjects must satisfy the following additional criteria prior to entry of the booster\n        phase:\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Previous vaccination with meningococcal polysaccharide or conjugate vaccine outside\n             of study MENACWY-TT-015.\n\n          -  History of meningococcal disease due to serogroup A, C, W-135 or Y.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including\n             Human Immunodeficiency Virus (HIV) infection, based on medical history and physical\n             examination.\n\n          -  Major congenital defects or serious chronic illness.\n\n          -  Family history of congenital or hereditary immunodeficiency.\n\n          -  History of chronic alcohol consumption and/or drug abuse.\n\n        Additional exclusion criteria for booster phase at Month 120 study entry (to be checked at\n        Month 120) for all subjects\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the booster dose of study vaccine, or planned use during the\n             follow-up period.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within six months prior to the booster vaccine dose.\n             Inhaled and topical steroids are allowed.\n\n          -  Administration of a vaccine not foreseen by the study protocol in the period starting\n             30 days before the booster dose of study vaccine or planned administration within 30\n             days after vaccination (with the day of vaccination considered Day 0), with the\n             exception of a licensed inactivated influenza vaccine.\n\n          -  Administration of immunoglobulins and/or any blood products within the three months\n             preceding the booster vaccination or planned administration during the follow-up\n             period.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product.\n\n          -  Previous vaccination with tetanus toxoids within the last month.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccines.\n\n          -  History of any neurological disorders or seizures, including Guillain-Barr\u00e9 syndrome\n             (GBS). History of a simple, single febrile seizure is permitted.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C for oral, axillary or tympanic route,\n                  or \u2265 38.0\u00b0C for rectal route. The preferred route for recording temperature in\n                  this study will be oral.\n\n               -  Subjects with a minor illness without fever may, be enrolled at the discretion\n                  of the investigator.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "66 Years", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934140", 
            "org_study_id": "116725"
        }, 
        "intervention": {
            "arm_group_label": [
                "MenPS group", 
                "ACWY-TT group"
            ], 
            "description": "1 dose administered intramuscularly in the non-dominant deltoid region.", 
            "intervention_name": "Meningococcal vaccine GSK134612", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Healthy", 
            "Adults", 
            "Safety", 
            "Neisseria meningitidis", 
            "Booster response", 
            "Immunogenicity", 
            "Adolescents", 
            "Serogroups A, C, W-135, and Y", 
            "long-term antibody persistence"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Muntinlupa", 
                    "country": "Philippines", 
                    "zip": "1781"
                }, 
                "name": "GSK Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Philippines: Philippines Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titres \u2265 1:8, \u2265 1:128 and geometric mean titres (GMTs)", 
            "measure": "Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titres", 
            "safety_issue": "No", 
            "time_frame": "During the long-term follow-up phase (6, 7, 8, 9 and 10 years after primary vaccination in Study MENACWY-TT-015)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titres and antibody concentration", 
                "safety_issue": "No", 
                "time_frame": "One month post booster vaccination at ten years after primary vaccination"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Days 0-3 following the booster vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited symptoms", 
                "safety_issue": "No", 
                "time_frame": "Up to 31 days following booster vaccination"
            }, 
            {
                "measure": "Occurrence of serious AEs, and new onset chronic illness(es) (e.g. autoimmune disorders, asthma, type 1 diabetes and allergies), GBS (Guillain-Barre Syndrome) and meningococcal disease", 
                "safety_issue": "No", 
                "time_frame": "From administration of the vaccine dose until study end (Month 126)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}